Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Lars Siegfried Maier
In the first talk of this translational symposium, Dr. Papp from Debrecen, Hungary presented an overview on the role of post-translational modifications of titin and other sarcomeric proteins in left ventricular diastolic dysfunction and diabetes.
This was followed by the presentation of Dr. Diez from Pamplona, Spain who talked about extracellular matrix. Besides the amount of collagen and its distribution (collagen I vs. III) also the type of collagen (soluble vs. insoluble) seems to play a role for HFpEF. One important protein altering collagen homeostastis is lysyl oxidase (LOX). In a clinical approach, torasemide seems to decrease LOX and results in favorable effects on diastolic function in contrast to furosemide.
Dr. Lam from Singapore elegantly presented a case of a woman with pulmonary hypertension most likely due to diastolic heart failure pointing to the role of vascular remodeling in HFpEF. In contrast to nitroglycerin, sodium nitroprusside improved haemodynamic parameters in the patient. An innovative clinical approach seems to be phosphodiesterase inhibition using sildenafil where a clinical trial is (RELAX) is currently performed.
Finally, Dr. Melenovsky from Prague convincingly showed that atrial dysfunction and chronotropic incompetence of the atria contribute significantly to the clinical phenotype of HFpEF. Although the Frank-Starling mechansim can be also found in the atria, increased fibrotic tissue which, interestingly, is unevenly distributed throughout the atria and older age are important contributors to altered atrial function.
Pathophysiology of heart failure with preserved ejection fraction